Cambridge Healthtech Institute's Inaugural

CRISPR for Genome Engineering

( ゲノムエンジニアリングのためのCRISPR )

創薬と治療薬開発を一変させる技術

2018年5月2-3日 | World Trade Center | マサチューセッツ州ボストン

The field of genome editing is at the tip of the iceberg, where discovery of new nucleases, development of novel CRISPR applications in genome engineering, gene silencing, screening, disease modeling, therapeutics and epigenomics are occurring rapidly. Despite the immense potential of CRISPR, the technology still needs to overcome challenges in its precision and efficiency in delivery, as well as reducing off-target mutations.

Introduced at PEGS Boston for the first time, CRISPR for Genome Engineering invites experts to share their experiences on harnessing CRISPR for drug discovery and therapeutic applications, and to discuss strategies to overcome its technological challenges.

Final Agenda

5月2日 (水)

7:30 am Registration and Morning Coffee

創薬と新たな遺伝子の同定

8:30 Chairperson's Remarks

John Feder, PhD, Associate Director, Genome Biology, Bristol-Myers Squibb

8:40 Cellular Engineering for Drug Discovery

Aaron_ChengAaron T. Cheng, PhD, Head, PTS Discovery Genome Editing, Protein Cellular and Structural Sciences, R&D Platform Technology & Science, GlaxoSmithKline

This talk will highlight our application and learnings from use of CRISPR genome editing in building cellular systems for drug discovery.

9:10 Genome-Wide CRISPR Screens Identify New Genes and Pathways Driving Breast Cancer Development and Progression

Gus Frangou, PhD, Fellow, Molecular and Integrative Physiological Sciences, Harvard TH Chan School of Public Health

Identifying genetic drivers of metastatic breast cancer and the timing during which these lesions occur is critical to developing effective therapeutics. In this talk, novel modifications of CRISPR/Cas9 genome-editing technology we have developed, including high-efficiency in vivo phenotypic screens and inducible gene targeting, to interrogate the functions of cancer-driver mutations will be discussed. Significantly, these CRISPR/Cas9-based genetic screens provide a systematic phenotypic measurement of loss-of-function lesions in disease progression and provide novel insights into the molecular underpinnings of metastasis.

9:40 Dissecting Complex Biological Processes with Pooled CRISPR-Cas9 Screens

Patrick_CollinsPatrick Collins, PhD, Senior Scientist, Genome Analysis Unit, Amgen

Pooled CRISPR screens have been shown by multiple groups to significantly outperform shRNA technology for identifying fitness genes. While every pooled screen inherently measures fitness over time, we can also apply selection(s) to study nearly any cell autonomous phenotype of interest. We will discuss the application of pooled CRISPR screens to study complex biological processes such as mechanisms of resistance and host factors modulating viral vector infection.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:55 Development and Optimization of CRISPR Gene Editing for Drug Discovery Applications

John_FederJohn Feder, PhD, Associate Director, Genome Biology, Bristol-Myers Squibb


11:25 Antibody-Display Libraries in Mammalian Cells Created Using CRISPR/Cas9 and TALE Nucleases

Michael Dyson, PhD, CTO, Antibody Engineering, IONTAS, Ltd.

Using directed integration of antibody genes by CRISPR/Cas9 and TALE nucleases, we have constructed large libraries in mammalian cells containing a single antibody gene/cell. This has permitted construction of millions of monoclonal stable cell lines displaying IgG antibodies on their surface from which antibodies have been selected by flow cytometry for specificity, binding affinity, species cross-reactivity and expression level. Expression in production cell lines also enables high-throughput developability screening.

11:55 Genome-Scale Activation Screen Identifies a lncRNA Locus Regulating a Gene Neighborhood

Julia_JoungJulia Joung, Graduate Student. Biological Engineering, MIT

Mammalian genomes contain thousands of loci that transcribe long non-coding RNAs (lncRNAs). Despite their potentially important roles, it remains challenging to identify functional lncRNA loci. Here, we developed a CRISPR-Cas9 activation screen targeting >10,000 lncRNA loci and found 11 that mediate melanoma drug resistance. Detailed analysis of one candidate revealed that its transcriptional activation resulted in dosage-dependent activation of four neighboring genes, one of which confers the resistance phenotype.

12:25 pm Sponsored Presentation (Opportunity Available)

12:55 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on your Own

1:55 Session Break

2:10 Chairperson's Remarks

Aaron T. Cheng, PhD, Head, PTS Discovery Genome Editing, Protein Cellular and Structural Sciences, R&D Platform Technology & Science, GlaxoSmithKline


2:15 KEYNOTE PRESENTATION: Bringing CRISPR to the Clinic

Tony_HoTony Ho, MD, Executive Vice President, Head of R&D, CRISPR Therapeutics

I will be discussing the data that supports the first CRISPR-based cell therapy clinical trial for b-thalassemia, including selection of gRNA and evaluation of target events, efficacy of editing and pharmacodynamics effects. In addition, I will also discuss the use of CRISPR/Cas 9 in generating potent allogenic multi-edited CAR T therapeutics across variety of tumors.

遺伝子編集のための次世代シーケンシング

2:45 Development of a Qualifiable NGS Assay for Precise and Accurate Quantitation of Small Insertions and Deletions (Indels) That Are Introduced in the Human Genome by Gene Editing

Judith Greengard, PhD, RAC, Director, Bioanalytics and Development, Sangamo Therapeutics

Gene editing by targeted engineered nucleases in living cells is tracked by the detection of introduced indels (small insertions and deletions) at specific nucleotide sequences using Next-Generation Sequencing. Comparisons of nuclease efficiency and monitoring of results in patient samples requires the development of quantitative assays. The purpose of this talk is to discuss application of these established principles to the challenge of indel quantitation.

3:15 Sponsored Presentation (Opportunity Available)

3:45 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Problem-Solving Breakout Discussions

5:45 Networking Reception in the Exhibit Hall with Poster Viewing

7:00 End of Day

5月3日 (木)

8:00 am Morning Coffee

疾病モデルの作成

8:30 Chairperson's Remarks

Patrick Collins, PhD, Senior Scientist, Genome Analysis Unit, Amgen

8:35 Genome Editing to Model and Treat Cardiac and Neuromuscular Diseases

Chengzu_LongChengzu Long, PhD, Asst Professor, Department of Medicine, New York University

Our projects focus on advancing the novel genome editing technology to model and treat cardiac and neuromuscular diseases. Duchenne muscular dystrophy (DMD) is a fatal muscle disease affecting 1 in 3,500 boys. Dilated cardiomyopathy (DCM) and heart failure are common and lethal consequences of DMD. We have advanced genome editing to cells from DMD patients by engineering the permanent skipping of mutant exons in the genomes of DMD patient-derived induced pluripotent stem cells (iPSCs).

9:05 Modelling the Pathogenic Effect of Mutations in Rare Mendelian Conditions

Colin_JohnsonColin A. Johnson, PhD, Professor of Medical & Molecular Genetics, Section of Ophthalmology and Neurosciences, Leeds Institute of Molecular Medicine

To gain novel unbiased insights into essential biological processes and to identify roles for unanticipated pathways in human genetic disease, we have developed our existing gene discovery research to include cellular disease modelling using CRISPR-Cas9 genome and base editing approaches. We will discuss recent advances in modelling ciliopathies, neuromuscular and neurodevelopmental conditions, and inherited retinal dystrophies.

9:35 Sponsored Presentation (Opportunity Available)

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

CRISPRの代替的なデリバリーとアンチCRISPRの機構

11:05 An Alternative CRISPR Delivery Method

Kristian_LaursenKristian Laursen, PhD, Professor, Pharmacology, Cornell University

CRISPR has the potential to revolutionize healthcare as we know it. We utilize modified RNAs for a more efficient delivery and genome edit.


11:35 Structural Basis of CRISPR/Cas9 and Anti-CRISPR Mechanisms for Precise Genome Editing

Fuguo Jiang, PhD, Postdoc Fellow, Molecular and Cell Biology, University of California, Berkeley

CRISPR/Cas9 technology shows great promise in treating cancer diseases at a genetic level. The recently discovered natural Cas9-specific "anti-CRISPRs" present important tools that can be used to regulate CRISPR/Cas9-mediated genome editing specificity. I will talk about our structural studies on CRISPR/Cas9 and anti-CRISPR mechanisms, with the hope to support CRISPR/Cas9 site-specific genetic control and therapeutic applications.

12:05 pm CRISPR-Cas9 Inactivation by Bacteriophage Proteins

Bettie Osuna, PhD, Graduate Student, Bondy-Denomy Lab, University of California, San Francisco

CRISPR-Cas adaptive immune systems defend prokaryotes from invasion by foreign genetic elements, including viruses (bacteriophages/phages). Phages have coevolved counter-attack strategies, including inactivation of CRISPR-Cas with "anti-CRISPR" proteins. We have discovered proteins encoded by Listeria monocytogenes phages, AcrIIA1-4, that suppress CRISPR-Cas9 activity. Our work aims to characterize anti-CRISPR-Cas9 mechanisms in this natural context to gain insight into CRISPR-Cas9 evolution and allow the use of anti-CRISPRs as "off-switches" in gene editing applications.

12:35 End of CRISPR for Genome Engineering

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English